Home
Scholarly Works
Impact of clinical and molecular predictors of...
Conference

Impact of clinical and molecular predictors of benefit from erlotinib in advanced non-small cell lung cancer on cost-effectiveness

Authors

Bradbury PA; Tu D; Seymour L; Ng R; Zhu L; Isogai PK; Mittmann N; Evans WK; Shepherd FA; Leighl NB

Volume

26

Pagination

pp. 6531-6531

Publisher

American Society of Clinical Oncology (ASCO)

Publication Date

May 20, 2008

DOI

10.1200/jco.2008.26.15_suppl.6531

Conference proceedings

Journal of Clinical Oncology

Issue

15_suppl

ISSN

0732-183X
View published work (Non-McMaster Users)

Contact the Experts team